首页 > 最新文献

Breast disease最新文献

英文 中文
Eribulin in metastatic breast cancer: Real world data 转移性乳腺癌中的 Eribulin:真实世界数据
Pub Date : 2023-12-05 DOI: 10.3233/bd-230031
C. L. Fernández-Laguna, I. Maray, Lola Macia-Rivas, Cristina Álvarez-Asteinza, Sergio Fernández-Lastras, Veronica Velasco Durántez, Mónica Carbajales Álvarez, Ana Lozan-Blázquez
BACKGROUND: Metastatic breast cancer (MBC) is incurable. Systemic therapy is the standard treatment; however, an optimal sequence of chemotherapy has not been established. OBJECTIVE: Evaluating effectiveness and safety of eribulin in MBC treatment and comparing the results obtained with published literature. METHODS: Observational, descriptive and retrospective study of patients with MBC treated with eribulin from 01/12/2015 to 30/10/2021. Effectiveness was analysed using Kaplan–Meier-survival-curves, for the overall number of patients treated and stratified by treatment line. Safety was measured according to adverse events (AE) based on CTCAE v5.0. Data analysis was performed using R v4.0.1. RESULTS: They were included in this study 53 women who received eribulin (median age 58 years). Comparison of median survival from this study versus published data were: progression-free-survival (PFS) 3 (IC95%: 3–4) versus 3.7 months and overall-survival (OS) 8 (IC95%: 3–4) versus 13.2 months for the overall number of patients. For the 1–3 line treatment group, PFS was 6 (IC95%: 3-NA) and OS was 15 (IC95%: 6-NA). There were 322 AEs, the most frequent being blood disorders 16% (52), general disorders 12% (38), and gastrointestinal disorders 12% (38). CONCLUSIONS: The median PFS was similar to that reported previously, with lower OS. There was a tendency to achieve better results when eribulin was used earlier. Eribulin is a less well-tolerated drug than published literature.
背景:转移性乳腺癌(MBC)是无法治愈的。全身治疗是标准治疗;然而,一个最佳的化疗顺序尚未确定。目的:评价伊瑞布林治疗MBC的有效性和安全性,并与文献资料进行比较。方法:对2015年12月1日至2021年10月30日接受伊瑞布林治疗的MBC患者进行观察性、描述性和回顾性研究。使用kaplan - meier -生存曲线分析治疗总人数的有效性,并按治疗线分层。以CTCAE v5.0为标准,根据不良事件(AE)进行安全性评价。使用R v4.0.1进行数据分析。结果:本研究纳入53名接受伊瑞布林治疗的女性(中位年龄58岁)。该研究与已发表数据的中位生存期比较为:患者总人数的无进展生存期(PFS) 3 (IC95%: 3 - 4) vs 3.7个月,总生存期(OS) 8 (IC95%: 3 - 4) vs 13.2个月。对于1-3线治疗组,PFS为6 (IC95%: 3-NA), OS为15 (IC95%: 6- na)。共有322例ae,最常见的是血液疾病16%(52例),一般疾病12%(38例),胃肠道疾病12%(38例)。结论:中位PFS与之前报道的相似,OS较低。早期使用伊曲布林有取得更好效果的趋势。与已发表的文献相比,艾里布林是一种耐受性较差的药物。
{"title":"Eribulin in metastatic breast cancer: Real world data","authors":"C. L. Fernández-Laguna, I. Maray, Lola Macia-Rivas, Cristina Álvarez-Asteinza, Sergio Fernández-Lastras, Veronica Velasco Durántez, Mónica Carbajales Álvarez, Ana Lozan-Blázquez","doi":"10.3233/bd-230031","DOIUrl":"https://doi.org/10.3233/bd-230031","url":null,"abstract":"BACKGROUND: Metastatic breast cancer (MBC) is incurable. Systemic therapy is the standard treatment; however, an optimal sequence of chemotherapy has not been established. OBJECTIVE: Evaluating effectiveness and safety of eribulin in MBC treatment and comparing the results obtained with published literature. METHODS: Observational, descriptive and retrospective study of patients with MBC treated with eribulin from 01/12/2015 to 30/10/2021. Effectiveness was analysed using Kaplan–Meier-survival-curves, for the overall number of patients treated and stratified by treatment line. Safety was measured according to adverse events (AE) based on CTCAE v5.0. Data analysis was performed using R v4.0.1. RESULTS: They were included in this study 53 women who received eribulin (median age 58 years). Comparison of median survival from this study versus published data were: progression-free-survival (PFS) 3 (IC95%: 3–4) versus 3.7 months and overall-survival (OS) 8 (IC95%: 3–4) versus 13.2 months for the overall number of patients. For the 1–3 line treatment group, PFS was 6 (IC95%: 3-NA) and OS was 15 (IC95%: 6-NA). There were 322 AEs, the most frequent being blood disorders 16% (52), general disorders 12% (38), and gastrointestinal disorders 12% (38). CONCLUSIONS: The median PFS was similar to that reported previously, with lower OS. There was a tendency to achieve better results when eribulin was used earlier. Eribulin is a less well-tolerated drug than published literature.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"113 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138599587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic analysis of breast cancer patients from Kerala: A novel BRCA1 mutation detected 喀拉拉邦乳腺癌患者的基因组分析:检测到一种新的BRCA1突变
Pub Date : 2023-11-10 DOI: 10.3233/bd-220002
Adarsh Dharmarajan, Vipin Gopinath, Sangeetha Keloth Nayanar, Sobhith Velandi Kunnummal, Satheesan Balasubramanian, Deepak Roshan Valiyaparambil Gopi
BACKGROUND: Breast cancer is the most common cancer among females, with an incidence of 6,41,000 cases annually. The genetic makeup of the individuals, ethnicity, geographical location, lifestyle, and BMI are some well-described factors associated with breast cancer. It is well known that pathogenic variants in BRCA1 and BRCA2 are associated with a majority of hereditary breast cancer. Genome-wide association studies (GWAS) have identified more than 80 germline susceptibility loci responsible for hereditary breast cancer. METHODS: In the present study, analysis of 94 genes associated with hereditary cancer was performed using next generation sequencing (NGS) in twelve patients having breast cancer and suspected with hereditary association. RESULTS: Four out of twelve (33%) patients harbored pathogenic mutation of the BRCA1 gene. Two patients was identified p. E23Vfs*17 mutation in BRCA1, one patient had p.Glu1580Gln in BRCA1, and a novel frameshift variant p.T1456Ifs*9(c.4367Cdel) in one patient. CONCLUSION: In the present study, out of four detected mutations in the BRCA1 gene, three were known and one was a novel BRCA1 mutation. It is advised to perform NGS-based genome sequencing to identify the genetic predisposition in breast cancer patients.
背景:乳腺癌是女性中最常见的癌症,每年的发病率为641,000例。个体的基因组成、种族、地理位置、生活方式和身体质量指数是与乳腺癌相关的一些很好的因素。众所周知,BRCA1和BRCA2的致病变异与大多数遗传性乳腺癌有关。全基因组关联研究(GWAS)已经确定了80多个与遗传性乳腺癌相关的种系易感位点。方法:采用下一代测序(NGS)对12例疑似有遗传关联的乳腺癌患者进行94个与遗传性癌症相关的基因分析。结果:12例患者中有4例(33%)携带BRCA1基因致病性突变。2例患者在BRCA1中发现p. E23Vfs*17突变,1例患者在BRCA1中发现p. glu1580gln突变,1例患者发现新的移码变体p. t1456ifs *9(c.4367Cdel)。结论:在本研究中,检测到的4个BRCA1基因突变中,有3个是已知的,1个是新的BRCA1突变。建议采用基于ngs的基因组测序来确定乳腺癌患者的遗传易感性。
{"title":"Genomic analysis of breast cancer patients from Kerala: A novel BRCA1 mutation detected","authors":"Adarsh Dharmarajan, Vipin Gopinath, Sangeetha Keloth Nayanar, Sobhith Velandi Kunnummal, Satheesan Balasubramanian, Deepak Roshan Valiyaparambil Gopi","doi":"10.3233/bd-220002","DOIUrl":"https://doi.org/10.3233/bd-220002","url":null,"abstract":"BACKGROUND: Breast cancer is the most common cancer among females, with an incidence of 6,41,000 cases annually. The genetic makeup of the individuals, ethnicity, geographical location, lifestyle, and BMI are some well-described factors associated with breast cancer. It is well known that pathogenic variants in BRCA1 and BRCA2 are associated with a majority of hereditary breast cancer. Genome-wide association studies (GWAS) have identified more than 80 germline susceptibility loci responsible for hereditary breast cancer. METHODS: In the present study, analysis of 94 genes associated with hereditary cancer was performed using next generation sequencing (NGS) in twelve patients having breast cancer and suspected with hereditary association. RESULTS: Four out of twelve (33%) patients harbored pathogenic mutation of the BRCA1 gene. Two patients was identified p. E23Vfs*17 mutation in BRCA1, one patient had p.Glu1580Gln in BRCA1, and a novel frameshift variant p.T1456Ifs*9(c.4367Cdel) in one patient. CONCLUSION: In the present study, out of four detected mutations in the BRCA1 gene, three were known and one was a novel BRCA1 mutation. It is advised to perform NGS-based genome sequencing to identify the genetic predisposition in breast cancer patients.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":" 15","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135190959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Axillary reverse mapping in breast cancer: An overview. 乳腺癌腋窝反向映射:综述。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220040
Yara Abbas, Omar Hamdy

Standard operative management for breast carcinoma has significantly shifted from extensive procedures to minor interventions.Although axillary dissection was a fundamental component of operative management, sentinel biopsy is an actual process for axillary staging. Axillary dissection may be postponed for cases that have negative SLNs or 1 or 2 infiltrated lymph nodes undergoing breast or axillary radiation. Contrarily, axillary dissection is still the conventional management for patients with clinically positive nodes.Arm lymphedema is a frequent and overwhelming complication of axillary dissection, with a worse impact on the patient's life.Axillary reverse mapping was recently introduced to map and conserve the lymph drain of the upper limb throughout axillary dissection or sentinel biopsy. A technique based on the theory that the breast's lymphatic drainage differs from those that drain the arm, so preserving lymphatic drainage of the upper limb can prevent lymphedema, thereby not raising the risk of axillary recurrence.Therefore, this technique is the reverse of sentinel biopsy, which remove the lymph nodes that drain the breast.

乳腺癌的标准手术管理已明显从广泛的手术转向小的干预。虽然腋窝解剖是手术处理的基本组成部分,前哨活检是腋窝分期的实际过程。对于sln阴性或1或2个浸润淋巴结接受乳腺或腋窝放疗的病例,腋窝清扫可推迟进行。相反,腋窝清扫仍然是临床阳性淋巴结患者的常规处理方法。上肢淋巴水肿是腋窝夹层的常见并发症,严重影响患者的生活。腋窝反向测绘最近被引入,通过腋窝解剖或前哨活检来绘制和保存上肢的淋巴引流。一种基于以下理论的技术:乳房的淋巴引流与手臂的淋巴引流不同,因此保留上肢的淋巴引流可以预防淋巴水肿,从而不会增加腋窝复发的风险。因此,这项技术与前哨活检相反,后者切除了乳腺的淋巴结。
{"title":"Axillary reverse mapping in breast cancer: An overview.","authors":"Yara Abbas,&nbsp;Omar Hamdy","doi":"10.3233/BD-220040","DOIUrl":"https://doi.org/10.3233/BD-220040","url":null,"abstract":"<p><p>Standard operative management for breast carcinoma has significantly shifted from extensive procedures to minor interventions.Although axillary dissection was a fundamental component of operative management, sentinel biopsy is an actual process for axillary staging. Axillary dissection may be postponed for cases that have negative SLNs or 1 or 2 infiltrated lymph nodes undergoing breast or axillary radiation. Contrarily, axillary dissection is still the conventional management for patients with clinically positive nodes.Arm lymphedema is a frequent and overwhelming complication of axillary dissection, with a worse impact on the patient's life.Axillary reverse mapping was recently introduced to map and conserve the lymph drain of the upper limb throughout axillary dissection or sentinel biopsy. A technique based on the theory that the breast's lymphatic drainage differs from those that drain the arm, so preserving lymphatic drainage of the upper limb can prevent lymphedema, thereby not raising the risk of axillary recurrence.Therefore, this technique is the reverse of sentinel biopsy, which remove the lymph nodes that drain the breast.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"137-146"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pseudoangiomatous stromal hyperplasia of the breast, imaging and clinical perspective: A review. 乳腺假性血管瘤间质增生、影像学及临床研究进展。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220072
Afsaneh Alikhassi, Mia Skarpathiotakis, Fang-L Lu, Belinda Curpen

Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast pathology, which most commonly presents incidentally along with other breast pathologies. The etiology and pathogenesis of PASH are still unknown; however, there is some evidence suggesting PASH is hormone dependent. The clinical history, presentation, and imaging appearance of PASH are variable. Clinically, PASH has a wide spectrum of presentations, from being silent to gigantomastia. On imaging, PASH demonstrates various benign to suspicious features. Here we summarize PASH's clinical presentation, histopathology, imaging features, and management.

假性血管瘤间质增生(PASH)是一种良性乳腺病理,通常与其他乳腺病理同时出现。PASH的病因和发病机制尚不清楚;然而,有证据表明PASH依赖于激素。PASH的临床病史、表现和影像学表现各不相同。临床上,PASH有广泛的表现,从沉默到巨乳症。在影像学上,PASH表现出各种良性到可疑的特征。在此,我们总结PASH的临床表现、组织病理学、影像学特征和治疗。
{"title":"Pseudoangiomatous stromal hyperplasia of the breast, imaging and clinical perspective: A review.","authors":"Afsaneh Alikhassi,&nbsp;Mia Skarpathiotakis,&nbsp;Fang-L Lu,&nbsp;Belinda Curpen","doi":"10.3233/BD-220072","DOIUrl":"https://doi.org/10.3233/BD-220072","url":null,"abstract":"<p><p>Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast pathology, which most commonly presents incidentally along with other breast pathologies. The etiology and pathogenesis of PASH are still unknown; however, there is some evidence suggesting PASH is hormone dependent. The clinical history, presentation, and imaging appearance of PASH are variable. Clinically, PASH has a wide spectrum of presentations, from being silent to gigantomastia. On imaging, PASH demonstrates various benign to suspicious features. Here we summarize PASH's clinical presentation, histopathology, imaging features, and management.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"147-153"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality assessment of breast cancer studies conducted with the Delphi technique. 用德尔菲技术对乳腺癌研究进行质量评估。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220079
Daniela Patino-Hernandez, Daniel G Fernández-Ávila, Óscar Mauricio Muñoz-Velandia, Isabel Del Socorro Moreno Luna

Background: The Delphi technique is a consensus method aiming to obtain statistical estimations from a qualitative approach, through an iterative process that leads to consensus within experts. The main characteristics of the technique include iteration, anonymity, feedback, and consensus reaching. When high-quality, quantitative evidence on a particular topic is insufficient, the Delphi technique can be used for making decisions in clinical scenarios. However, the quality of studies on breast cancer conducted with this technique, has not been assessed.

Objective: We aim to evaluate the quality of studies on breast cancer which used the Delphi technique as their method.

Methods: A quality assessment tool (Quali-D) was created through consensus among experts on the Delphi technique. Then, the tool was applied to studies on breast cancer which used the Delphi technique as their method.

Results: Studies conducted through the Delphi technique mainly assessed for quality indicators and expressed needs in patients with breast cancer. High-quality characteristics were reported in 63.89% of the studies. 98.61% used the Delphi technique due to lack of a more adequate method to solve their research question. 98.61% summarized and presented results in a clear way. In 91.67% of the studies, at least two rounds were conducted. 86.11% described the methods for expert selection in a complete manner. Only 54.17% of the studies reported an anonymous process and 4.17% of the studies disclosed conflicts of interest thoroughly.

Conclusions: A variety of topics were assessed through the Delphi technique in cases where no other technique would have been more appropriate for assessing these issues. Significant limitations are present in terms of anonymity and full disclosure of conflicts of interest. We found that the quality of studies conducted with the Delphi technique regarding breast cancer is overall good. However, the limitations of each study must be considered when applying their results to clinical practice.

背景:德尔菲技术是一种共识方法,旨在通过迭代过程从定性方法中获得统计估计,从而在专家内部达成共识。该技术的主要特点包括迭代、匿名、反馈和达成共识。当某一特定主题的高质量、定量证据不足时,德尔菲技术可用于在临床场景中做出决策。然而,用这种技术进行的乳腺癌研究的质量尚未得到评估。目的:评价用德尔菲法进行乳腺癌研究的质量。方法:采用德尔菲法,经专家协商一致,建立质量评价工具(quality - d)。然后,将该工具应用于以德尔菲技术为方法的乳腺癌研究。结果:通过德尔菲技术进行的研究主要是对乳腺癌患者的质量指标和表达需求进行评估。63.89%的研究报告了高质量特征。由于缺乏一种更充分的方法来解决他们的研究问题,98.61%的人使用德尔菲技术。98.61%对结果进行了清晰的总结和呈现。91.67%的研究至少进行了两轮。86.11%的人完整地描述了专家选择的方法。只有54.17%的研究报告了匿名过程,4.17%的研究彻底披露了利益冲突。结论:在没有其他技术更适合评估这些问题的情况下,通过德尔菲技术评估了各种主题。在匿名和充分披露利益冲突方面存在重大限制。我们发现用德尔菲技术进行的关于乳腺癌的研究质量总体上是好的。然而,在将每项研究的结果应用于临床实践时,必须考虑其局限性。
{"title":"Quality assessment of breast cancer studies conducted with the Delphi technique.","authors":"Daniela Patino-Hernandez,&nbsp;Daniel G Fernández-Ávila,&nbsp;Óscar Mauricio Muñoz-Velandia,&nbsp;Isabel Del Socorro Moreno Luna","doi":"10.3233/BD-220079","DOIUrl":"https://doi.org/10.3233/BD-220079","url":null,"abstract":"<p><strong>Background: </strong>The Delphi technique is a consensus method aiming to obtain statistical estimations from a qualitative approach, through an iterative process that leads to consensus within experts. The main characteristics of the technique include iteration, anonymity, feedback, and consensus reaching. When high-quality, quantitative evidence on a particular topic is insufficient, the Delphi technique can be used for making decisions in clinical scenarios. However, the quality of studies on breast cancer conducted with this technique, has not been assessed.</p><p><strong>Objective: </strong>We aim to evaluate the quality of studies on breast cancer which used the Delphi technique as their method.</p><p><strong>Methods: </strong>A quality assessment tool (Quali-D) was created through consensus among experts on the Delphi technique. Then, the tool was applied to studies on breast cancer which used the Delphi technique as their method.</p><p><strong>Results: </strong>Studies conducted through the Delphi technique mainly assessed for quality indicators and expressed needs in patients with breast cancer. High-quality characteristics were reported in 63.89% of the studies. 98.61% used the Delphi technique due to lack of a more adequate method to solve their research question. 98.61% summarized and presented results in a clear way. In 91.67% of the studies, at least two rounds were conducted. 86.11% described the methods for expert selection in a complete manner. Only 54.17% of the studies reported an anonymous process and 4.17% of the studies disclosed conflicts of interest thoroughly.</p><p><strong>Conclusions: </strong>A variety of topics were assessed through the Delphi technique in cases where no other technique would have been more appropriate for assessing these issues. Significant limitations are present in terms of anonymity and full disclosure of conflicts of interest. We found that the quality of studies conducted with the Delphi technique regarding breast cancer is overall good. However, the limitations of each study must be considered when applying their results to clinical practice.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"155-161"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast reconstruction for locally advanced breast cancer previously submitted to mastectomy and an ipsilateral thoracoabdominal dermofat (ITADE) flap. 局部晚期乳腺癌的乳房重建先前提交乳房切除术和同侧胸腹真皮脂肪(ITADE)皮瓣。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220057
René Aloisio da Costa Vieira, An Wan Ching, Idam de Oliveira-Junior

Thoracoabdominal (TA) flaps are a good option for primary closure of small and medium defects after mastectomy for locally advanced breast tumours. Although they have a higher rate of necrosis than myocutaneous flaps, they can be easily performed by breast surgeons. Few studies on this procedure have been reported, and we have been unable to identify any prior publications reporting breast reconstruction with TA flaps.

胸腹皮瓣是局部晚期乳房肿瘤切除后中小型乳房缺损的良好选择。虽然它们比肌皮瓣有更高的坏死率,但它们可以很容易地被乳房外科医生实施。很少有关于该手术的研究被报道,我们也无法找到任何先前报道用TA瓣重建乳房的出版物。
{"title":"Breast reconstruction for locally advanced breast cancer previously submitted to mastectomy and an ipsilateral thoracoabdominal dermofat (ITADE) flap.","authors":"René Aloisio da Costa Vieira,&nbsp;An Wan Ching,&nbsp;Idam de Oliveira-Junior","doi":"10.3233/BD-220057","DOIUrl":"https://doi.org/10.3233/BD-220057","url":null,"abstract":"<p><p>Thoracoabdominal (TA) flaps are a good option for primary closure of small and medium defects after mastectomy for locally advanced breast tumours. Although they have a higher rate of necrosis than myocutaneous flaps, they can be easily performed by breast surgeons. Few studies on this procedure have been reported, and we have been unable to identify any prior publications reporting breast reconstruction with TA flaps.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"229-232"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9907779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GLIS2 and CCND1 expression levels in breast cancer patients. GLIS2和CCND1在乳腺癌患者中的表达水平。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220068
Minoosh Sadeghi, Majid Gholizadeh, Neda Safataj, Mahsa Tahmasebivand, Gholamreza Mohajeri, Hajie Lotfi, Saber Yari Bostanabad, Behnaz Safar, Mansoor Salehi

Background: Breast cancer (BC) is the most prevalent cancer in women, with increasing incidence and death rates in recent years. Disruptions of different signaling pathways partially cause breast cancer. Hence, different genes through particular pathways are involved in BC tumorigenesis.

Methods: In this study, we evaluated the expression level of GLIS2 and CCND1 genes in 50 patients. Also, in-silico analyses were used to enrich related signaling pathways involving the mentioned genes.

Results: The results showed an increased expression level of Cyclin D1 and decreased expression level of GLIS2 in BC patients. Moreover, a relationship between aberrant expression levels of GLIS2 and CCND1 and BC development was determined.

Conclusion: These observations could help uncover new therapeutic targets for treating patients with BC in the progressive stage.

背景:乳腺癌(BC)是女性中最常见的癌症,近年来发病率和死亡率不断上升。不同信号通路的中断部分导致乳腺癌。因此,不同的基因通过特定的途径参与了BC肿瘤的发生。方法:本研究对50例患者GLIS2和CCND1基因的表达水平进行了检测。此外,利用芯片分析丰富了涉及上述基因的相关信号通路。结果:BC患者中Cyclin D1表达水平升高,GLIS2表达水平降低。此外,我们还确定了GLIS2和CCND1的异常表达水平与BC发展之间的关系。结论:这些观察结果有助于发现治疗进展期BC患者的新治疗靶点。
{"title":"GLIS2 and CCND1 expression levels in breast cancer patients.","authors":"Minoosh Sadeghi,&nbsp;Majid Gholizadeh,&nbsp;Neda Safataj,&nbsp;Mahsa Tahmasebivand,&nbsp;Gholamreza Mohajeri,&nbsp;Hajie Lotfi,&nbsp;Saber Yari Bostanabad,&nbsp;Behnaz Safar,&nbsp;Mansoor Salehi","doi":"10.3233/BD-220068","DOIUrl":"https://doi.org/10.3233/BD-220068","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is the most prevalent cancer in women, with increasing incidence and death rates in recent years. Disruptions of different signaling pathways partially cause breast cancer. Hence, different genes through particular pathways are involved in BC tumorigenesis.</p><p><strong>Methods: </strong>In this study, we evaluated the expression level of GLIS2 and CCND1 genes in 50 patients. Also, in-silico analyses were used to enrich related signaling pathways involving the mentioned genes.</p><p><strong>Results: </strong>The results showed an increased expression level of Cyclin D1 and decreased expression level of GLIS2 in BC patients. Moreover, a relationship between aberrant expression levels of GLIS2 and CCND1 and BC development was determined.</p><p><strong>Conclusion: </strong>These observations could help uncover new therapeutic targets for treating patients with BC in the progressive stage.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"251-259"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10024946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of risk factors and marker status in women with breast cancer in Brunei Darussalam. 文莱达鲁萨兰国妇女乳腺癌危险因素及标志物状况的研究。
Pub Date : 2023-01-01 DOI: 10.3233/BD-239001
Chieng Bing Wong, Aklimah Mustapa, Siti Nur Idayu Matusin, Muhammad Syafiq Abdullah, Andi Nilawati Usman, Mas Rina Wati Haji Abdul Hamid

Objective: To investigate the associations between breast cancer staging and body mass index (BMI), menopausal status, and family history of breast cancer, as well as to assess the expression of tumor markers in women with breast cancer in Brunei Darussalam.

Methods: A retrospective cross-sectional study was carried out at The Brunei Cancer Centre. Cases of women with breast cancer between 2000 and 2013 were retrieved from the medical records section and entered into a clinical proforma. These were reviewed and analyzed using appropriate statistical methods.

Results: Overall, the mean age at diagnosis was 53.6 years ± 9.83. The postmenopausal women had a significantly higher risk of being diagnosed with late-onset breast cancer than premenopausal women (P = 0.022). The expressions of PR (P = 0.034), Her2 (P = 0.046), and CatD (P = 0.004) were significantly different in breast cancer staging. Other factors did not have a statistically-significant association with breast cancer staging.

Conclusion: While most of the factors studied were not significantly different in breast cancer staging, our findings showed that it is recommended that high-risk women perform regular breast screening after the age of 40 years old. A future study highly appreciates comparing breast cancer risk factors among the Bruneian and Western populations.

目的:探讨文莱达鲁萨兰国乳腺癌分期与体重指数(BMI)、绝经状况、乳腺癌家族史的关系,并评估肿瘤标志物在乳腺癌妇女中的表达。方法:在文莱癌症中心进行回顾性横断面研究。从医疗记录部分检索2000年至2013年期间患乳腺癌的妇女病例,并输入临床形式表。使用适当的统计方法对这些进行了审查和分析。结果:总体而言,平均诊断年龄为53.6岁±9.83岁。绝经后妇女被诊断为晚发型乳腺癌的风险明显高于绝经前妇女(P = 0.022)。PR (P = 0.034)、Her2 (P = 0.046)、CatD (P = 0.004)在乳腺癌分期中的表达差异有统计学意义。其他因素与乳腺癌分期没有统计学上的显著关联。结论:虽然所研究的大多数因素在乳腺癌分期方面没有显著差异,但我们的研究结果表明,建议高危女性在40岁以后定期进行乳房筛查。一项未来的研究高度赞赏在文莱和西方人群中比较乳腺癌的危险因素。
{"title":"Study of risk factors and marker status in women with breast cancer in Brunei Darussalam.","authors":"Chieng Bing Wong,&nbsp;Aklimah Mustapa,&nbsp;Siti Nur Idayu Matusin,&nbsp;Muhammad Syafiq Abdullah,&nbsp;Andi Nilawati Usman,&nbsp;Mas Rina Wati Haji Abdul Hamid","doi":"10.3233/BD-239001","DOIUrl":"https://doi.org/10.3233/BD-239001","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the associations between breast cancer staging and body mass index (BMI), menopausal status, and family history of breast cancer, as well as to assess the expression of tumor markers in women with breast cancer in Brunei Darussalam.</p><p><strong>Methods: </strong>A retrospective cross-sectional study was carried out at The Brunei Cancer Centre. Cases of women with breast cancer between 2000 and 2013 were retrieved from the medical records section and entered into a clinical proforma. These were reviewed and analyzed using appropriate statistical methods.</p><p><strong>Results: </strong>Overall, the mean age at diagnosis was 53.6 years ± 9.83. The postmenopausal women had a significantly higher risk of being diagnosed with late-onset breast cancer than premenopausal women (P = 0.022). The expressions of PR (P = 0.034), Her2 (P = 0.046), and CatD (P = 0.004) were significantly different in breast cancer staging. Other factors did not have a statistically-significant association with breast cancer staging.</p><p><strong>Conclusion: </strong>While most of the factors studied were not significantly different in breast cancer staging, our findings showed that it is recommended that high-risk women perform regular breast screening after the age of 40 years old. A future study highly appreciates comparing breast cancer risk factors among the Bruneian and Western populations.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"183-189"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10060047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical presentations and outcomes of young women aged <40 yrs with Ductal carcinoma in situ. 40岁以下年轻女性原位导管癌的临床表现和结果。
Pub Date : 2023-01-01 DOI: 10.3233/BD-230018
Zhiyan Yan, Joanne Ngeow, John Allen, Geok Hoon Lim

Introduction: Ductal carcinoma in situ (DCIS) in young women is rare and not well studied. Since they do not qualify for mammographic screening, they are more likely to present with symptoms. Young women have also been associated with poorer outcomes, but it is unknown whether presentation mode affects outcome. We aimed to compare characteristics of DCIS patients <40 years of age presenting with symptoms versus those without, and determine whether presentation mode affects recurrence.

Methods: Pure DCIS patients aged <40 years were retrospectively analyzed. Clinical presentation, pathology and recurrence data were collected. Statistical analysis was performed to investigate the correlation of presentation mode with outcomes.

Results: 40 patients with 41 cases were included. The mean age at diagnosis was 32.3 years (range 17-39). 73.2% and 26.8% presented with symptoms or abnormal imaging respectively. Of the cases who presented with symptoms, 86.7%, 10.0% and 3.3% had palpable lump, nipple discharge or breast pain, respectively. The average tumor size was 22.0 mm (range 2.0-86.9) and 12.2 mm (range 3-25) for patients who presented with symptoms and non-symptomatic group, respectively. Cases presenting with symptoms were statistically associated with higher grade (p = 0.0090). On median follow-up of 85 months, there were 3 (7.3%) recurrences, which were not statistically associated with presentation mode.

Conclusion: Young women with DCIS tend to present with symptoms, with breast lump as the commonest symptom. Symptomatic patients tend to be associated with grade III tumours, compared to non-symptomatic patients. On long-term follow-up, mode of presentation was not statistically associated with recurrence.

引言:年轻女性的导管原位癌(DCIS)很少见,研究也不充分。由于他们没有资格接受乳房X光检查,他们更有可能出现症状。年轻女性也与较差的结果有关,但尚不清楚表现模式是否会影响结果。我们旨在比较DCIS患者的特征。方法:年龄为纯DCIS患者。结果:纳入40例患者,41例。诊断时的平均年龄为32.3岁(范围17-39岁)。73.2%和26.8%的患者出现症状或影像学异常。在出现症状的病例中,86.7%、10.0%和3.3%的患者有可触摸的肿块、乳头分泌物或乳房疼痛。有症状组和无症状组的平均肿瘤大小分别为22.0 mm(范围2.0-86.9)和12.2 mm(范围3-25)。有症状的病例在统计学上与更高的分级相关(p=0.0090)。在85个月的中位随访中,有3例(7.3%)复发,与表现模式没有统计学相关性。结论:DCIS的年轻女性往往表现出症状,其中乳腺肿块是最常见的症状。与无症状患者相比,有症状的患者往往与III级肿瘤相关。在长期随访中,表现方式与复发无统计学相关性。
{"title":"Clinical presentations and outcomes of young women aged <40 yrs with Ductal carcinoma in situ.","authors":"Zhiyan Yan,&nbsp;Joanne Ngeow,&nbsp;John Allen,&nbsp;Geok Hoon Lim","doi":"10.3233/BD-230018","DOIUrl":"10.3233/BD-230018","url":null,"abstract":"<p><strong>Introduction: </strong>Ductal carcinoma in situ (DCIS) in young women is rare and not well studied. Since they do not qualify for mammographic screening, they are more likely to present with symptoms. Young women have also been associated with poorer outcomes, but it is unknown whether presentation mode affects outcome. We aimed to compare characteristics of DCIS patients <40 years of age presenting with symptoms versus those without, and determine whether presentation mode affects recurrence.</p><p><strong>Methods: </strong>Pure DCIS patients aged <40 years were retrospectively analyzed. Clinical presentation, pathology and recurrence data were collected. Statistical analysis was performed to investigate the correlation of presentation mode with outcomes.</p><p><strong>Results: </strong>40 patients with 41 cases were included. The mean age at diagnosis was 32.3 years (range 17-39). 73.2% and 26.8% presented with symptoms or abnormal imaging respectively. Of the cases who presented with symptoms, 86.7%, 10.0% and 3.3% had palpable lump, nipple discharge or breast pain, respectively. The average tumor size was 22.0 mm (range 2.0-86.9) and 12.2 mm (range 3-25) for patients who presented with symptoms and non-symptomatic group, respectively. Cases presenting with symptoms were statistically associated with higher grade (p = 0.0090). On median follow-up of 85 months, there were 3 (7.3%) recurrences, which were not statistically associated with presentation mode.</p><p><strong>Conclusion: </strong>Young women with DCIS tend to present with symptoms, with breast lump as the commonest symptom. Symptomatic patients tend to be associated with grade III tumours, compared to non-symptomatic patients. On long-term follow-up, mode of presentation was not statistically associated with recurrence.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"299-303"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41092631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast amyloidosis associated with Sjögren syndrome: A diagnostic pitfall in breast pathology. 与斯约格伦综合征相关的乳腺淀粉样变性:乳腺病理诊断中的一个陷阱。
Pub Date : 2023-01-01 DOI: 10.3233/BD-230006
Oumeima Khaldi, Montassar Ghalleb, Amani Jallali, Insaf Fenniche, Mehdi Somai, Fatma Daoud, Fatma Boussema, Salma Kammoun, Khadija Hamza, Med Ali Ayadi, Tarek Dhieb

Background: Amyloidosis is an uncommon disorder characterized by the extracellular deposition of amorphous and insoluble proteins in an abnormal fibrillary configuration. Mammary amyloidosis is an unusual and easily overlooked diagnosis with an ambivalent presentation that could mimic breast cancer.

Case report: We here report the case of 60-year-old Caucasian woman who presented to our surgical oncology department for clinically and radiologically suspicious breast mass. A fine needle biopsy was irrelevant, so we performed a lumpectomy. Final histology revealed an amyloid deposit and further workup was consistent with nodular cutaneous and breast AL amyloidosis associated with Sjögren's syndrome.

Conclusion: Although rare, an awareness of the clinicopathologic characteristics of this easily overlooked entity is of great importance for breast surgeons.

背景:淀粉样变性是一种不常见的疾病,其特征是无定形和不溶性蛋白质在细胞外沉积成异常的纤维状结构。乳腺淀粉样变性是一种不常见且容易被忽视的诊断,其表现不明确,可能与乳腺癌相似:病例报告:我们在此报告了一例 60 岁的白种女性病例,她因临床和影像学上可疑的乳房肿块而到肿瘤外科就诊。细针穿刺活检并不相关,因此我们进行了肿块切除术。最后的组织学检查发现了淀粉样沉积物,进一步检查结果与结节性皮肤和乳腺AL淀粉样变性伴斯约格伦综合征一致:结论:虽然这种病很少见,但了解这种容易被忽视的疾病的临床病理特征对乳腺外科医生来说非常重要。
{"title":"Breast amyloidosis associated with Sjögren syndrome: A diagnostic pitfall in breast pathology.","authors":"Oumeima Khaldi, Montassar Ghalleb, Amani Jallali, Insaf Fenniche, Mehdi Somai, Fatma Daoud, Fatma Boussema, Salma Kammoun, Khadija Hamza, Med Ali Ayadi, Tarek Dhieb","doi":"10.3233/BD-230006","DOIUrl":"https://doi.org/10.3233/BD-230006","url":null,"abstract":"<p><strong>Background: </strong>Amyloidosis is an uncommon disorder characterized by the extracellular deposition of amorphous and insoluble proteins in an abnormal fibrillary configuration. Mammary amyloidosis is an unusual and easily overlooked diagnosis with an ambivalent presentation that could mimic breast cancer.</p><p><strong>Case report: </strong>We here report the case of 60-year-old Caucasian woman who presented to our surgical oncology department for clinically and radiologically suspicious breast mass. A fine needle biopsy was irrelevant, so we performed a lumpectomy. Final histology revealed an amyloid deposit and further workup was consistent with nodular cutaneous and breast AL amyloidosis associated with Sjögren's syndrome.</p><p><strong>Conclusion: </strong>Although rare, an awareness of the clinicopathologic characteristics of this easily overlooked entity is of great importance for breast surgeons.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"401-405"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138794598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Breast disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1